Akseli Hemminki. TILT Biotherapeutics CEO
February 7, 2023 07:24 AM EST
Financing

On­colyt­ic virus start­up TILT rais­es €22M to ad­vance can­cer ther­a­pies

Katherine Lewin

News Reporter

Fin­land-based TILT Bio­ther­a­peu­tics an­nounced to­day it raised €22 mil­lion in the fi­nal close of a sec­ond round of fi­nanc­ing to push its on­colyt­ic virus pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times